Table 4: Association of Oncoytpe-DX with overall survival in women with lymph-node-positive disease.
| Study | N (Events) [Outcome] |
KM Risk of 10-Year Death Due to Any Cause (95% CI) |
P-Value for Test of Significance |
Multivariate Cox Proportional HR for 50-point Increment in Continuous RS |
||
|---|---|---|---|---|---|---|
| High | Intermediate | Low | ||||
| Albain 2010 (SWOG 8814) (26) |
148 (66) | 48.6 | 31.9 | 22.9 | 0.003* | 4.42 (1.96–9.97) P-value 0.0006 |
| Dowsett 2009 (ATAC) (29) |
306 (74) | 46.0 | 31.0 | 26.0 | 0.002* | NR |
*
Log-rank test of equality between all KM risk groups
Abbreviations: ATAC, Arimidex, Tamoxifen, Alone or in Combination; CI, confidence interval; DFS, disease-free survival; DR, distant recurrence; HR, hazard ratio; KM, Kaplan-Meier; N, sample size; NR, not reported; RS, recurrence score; SWOG, Southwest Oncology Group; yr, year